Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

INTRODUCTION: Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients with moderate to severe active rheumatoid arthritis (RA). METHODS: This non-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Rheumatol Ther
Autori principali: Hilliquin, Pascal, Barnetche, Thomas, Baillet, Athan, Flipo, René-Marc, Lespessailles, Eric, Roux, Christian, Fardellone, Patrice, Gilbert-Marceau, Anika, Idier, Isabelle, Constantin, Arnaud, Shipley, Emilie, Baudens, Guy, Saraux, Alain
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7991027/
https://ncbi.nlm.nih.gov/pubmed/33216287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-020-00253-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi